Movement Alert｜Natera Falls 3.24% in Regular Trading, Profit-Taking Emerges Despite Higher Price Target

Market Focus10-13

On October 13, Natera fell 3.24% in Regular Trading, trading at $384.24 per share with turnover of $37.97 million.

The move came even after Morgan Stanley raised its price target on Natera to $435 from $355 and maintained an Overweight rating, as the stock faced profit-taking pressure following a strong prior run.

Recent company developments have remained supportive, including FDA Breakthrough Device Designation for its multi-cancer early detection assay and regulatory approval in Japan for Signatera as a companion diagnostic in muscle-invasive bladder cancer. Natera has also continued to expand its oncology pipeline through new skin cancer and breast cancer studies, but weakness across biotechnology stocks limited the near-term impact of these positives.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment